A novel self-assemble peptide drug design of AKT1 for anaplastic thyroid cancer therapy
Anaplastic thyroid cancer (ATC) is an undifferentiated subtype of thyroid cancer with a markedly poor survival prognosis, estimated to occur 3–5 months after diagnosis. Akt activation is reportedly involved in tumorigenesis during ATC and represents a new therapeutic target. Based on the Akt1/bisubs...
Main Authors: | Chai, L. (Author), Li, R. (Author), Qiu, Z. (Author), Wang, K. (Author), Zhang, X. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier B.V.
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3β/ANG Signaling Pathway in Anaplastic Thyroid Cancer
by: Zhijian Jin, et al.
Published: (2017-12-01) -
Anaplastic thyroid cancer
by: Javier Martínez Navarro, et al.
Published: (2017-10-01) -
Genetic alterations in anaplastic thyroid carcinoma
by: M Rashid, et al.
Published: (2019-01-01) -
Clinico-pathological profile of anaplastic thyroid carcinoma in an endemic goiter area
by: Roma Pradhan, et al.
Published: (2018-01-01) -
Investigation of the Validity of UICC Stage Grouping of Anaplastic Carcinoma of the Thyroid
by: Yasuhiro Ito, et al.
Published: (2009-01-01)